Trial Profile
Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Liver metastases; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Results assessing potential biomarkers in peripheral blood to predict response presented at the 114th Annual Meeting of the American Association for Cancer Research
- 12 Jan 2023 Planned primary completion date changed from 15 Jun 2023 to 15 Jul 2023.